Cancer Diagnostics - BioFluidica

BioFluidica CoFounder and CTO, Stephen Soper, on Facebook Live: Bench to Bedside.

The University of Kansas Cancer Center, January 20, 2019 Tune in February 20, 2019 as KU Cancer Center director Roy Jensen, MD, will host Steven Soper, PhD, KU [Read More...]

BioFluidica CoFounder and CTO, Stephen Soper, on Facebook Live: Bench to Bedside.david2022-11-03T10:13:12-07:00

BioFluidica Applying Liquid Biopsy to Detect Leukemia While Reducing Biopsies

genomeweb | By John Gilmore, January 17, 2019 NEW YORK (GenomeWeb) – Fresh off being awarded several grants by the National Institutes of Health, startup BioFluidica has [Read More...]

BioFluidica Applying Liquid Biopsy to Detect Leukemia While Reducing Biopsiesdavid2022-11-03T10:13:35-07:00

UNC Women’s Basketball Coach, Sylvia Hatchell’s Story

UNC Women’s Basketball Coach, Sylvia Hatchell’s Storydavid2022-11-03T09:35:21-07:00

In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemia

PR Newswire, January 10, 2019 SAN DIEGO /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, has been awarded an SBIR Phase II National Institutes of Health grant [Read More...]

In Promise of True Liquid Biopsy for Cancer, Chip Company BioFluidica® Awarded $1.7 Million by National Cancer Institute/National Institutes of Health for Clinical Trial in Children with Acute Lymphoblastic Leukemiadavid2022-11-03T10:14:36-07:00

BioFluidica turns to blood for accurate, inexpensive cancer tests

San Diego Union Tribune | By Bradley J. Fikes, August 31, 2018 Blood is hard to beat for detecting disease. This liquid tissue circulates throughout the body, picking up [Read More...]

BioFluidica turns to blood for accurate, inexpensive cancer testsdavid2022-11-03T10:16:17-07:00

In Promise of True Liquid Biopsy for Cancer, BioFluidica® Launches Human Trial for Rapid Detection of Minimal Residual Disease in Acute Myeloid Leukemia from Peripheral Blood Using high through-put automation and programmable Microfluidic Chips

PR Newswire, May 19, 2018 SAN DIEGO /PRNewswire/ -- BioFluidica, a privately held cancer diagnostics company, today announced the continuation of a highly successful small patient study [Read More...]

In Promise of True Liquid Biopsy for Cancer, BioFluidica® Launches Human Trial for Rapid Detection of Minimal Residual Disease in Acute Myeloid Leukemia from Peripheral Blood Using high through-put automation and programmable Microfluidic Chipsdavid2022-11-03T10:16:40-07:00